|
|
|
|
|
|
Companies > Clinical
|
|
|
TheraVasc is developing novel vascular therapies with decreased risks through the repositioning of drugs with known safety profiles. The company’s principal product is being advanced into clinical trials for treatment of chronic non-healing wounds. Other compounds under development address chronic disorders associated with reduced blood flow to the extremities.
Funders:
Portal Capital, JumpStart, North Coast Angel Fund
|
|
|
|
|